Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Histone deacetylases (HDACs) play a critical role in regulating gene expression during cancer initiation and progression.
• HDACs are increasingly recognized as significant therapeutic targets for novel anticancer agent development.
• Histone deacetylase inhibitors (HDACIs) represent a class of anticancer drugs with demonstrated tumor-selective cytotoxicity.

Purpose of the Study:

• To review recent advancements in the development of histone deacetylase inhibitors (HDACIs).
• To focus on the design strategies, novel chemical structures, biological properties, and structure-activity relationships (SARs) of HDACIs.
• To provide insights for medicinal chemists engaged in the discovery of anticancer agents.

Main Methods:

• Literature review of recent progress in HDACI development.
• Analysis of design strategies and chemical structures of various HDACIs.
• Examination of biological properties and structure-activity relationships (SARs) of HDACIs.

Main Results:

• HDACIs exhibit tumor-selective cytotoxicity, promoting cancer cell growth arrest, differentiation, and apoptosis.
• HDACIs possess minimal impact on normal tissues, indicating a favorable therapeutic window.
• Structurally diverse HDACIs have been developed and are utilized in clinical settings.

Conclusions:

• HDACIs are a promising class of anticancer drugs with significant therapeutic potential.
• Continued research into HDACI design, SARs, and biological properties is crucial for advancing cancer therapy.
• This review offers valuable information for medicinal chemists in the pursuit of novel anticancer agents.